Append Medical

Company Overview

Snapshot

Founded in November 2016 by Zachi Berger, Append Medical operates with 11–50 employees. The company has raised $12.55M across 4 funding rounds from 9 investors.

Business overview

Append Medical develops a minimally invasive implantable device designed to reduce stroke risk in patients with atrial fibrillation. Its core technology focuses on preventing blood clot leakage by achieving complete Left Atrial Appendage (LAA) closure, aiming to mitigate device-related thromboembolism risk by minimizing foreign material at the closure site. The company operates within the Health Tech & Life Sciences sector, specifically targeting the medical devices, cardiology, and cardiovascular markets with a focus on stroke prevention.

Strategic signal

In May 2026, Append Medical secured a B Round of funding, with Abbott participating as an investor. This investment signals strong strategic validation and potential for market adoption for Append Medical's trans-septal left atrial appendage closure device, indicating continued progress in its development and commercialization efforts within the cardiovascular medical device sector.

Company Intelligence Q&A

What is Append Medical's primary focus?

Append Medical is focused on developing a minimally invasive implantable device for trans-septal Left Atrial Appendage (LAA) closure, designed to reduce stroke risk in patients suffering from non-valvular atrial fibrillation.

When was Append Medical founded and by whom?

Append Medical was founded in November 2016 by Zachi Berger.